Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and ...
RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in ...
Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.
6don MSN
Weekly injection more effective for pregnant women with opioid use disorder, Ohio study suggests
CLEVELAND, Ohio — A longer-acting medication may be more effective at helping pregnant women with opioid use disorder avoid illegal drugs, suggests new research from the University of Cincinnati.
A recent study published in the Journal of the American Medical Association revealed that extended-release buprenorphine ...
In March 2026, Indivior Pharmaceuticals reported a new cost impact model in The Journal of Current Medical Research and Opinion showing that monthly extended-release buprenorphine injections ...
Leads to superior rates of illicit opioid abstinence and improved outcomes compared with sublingual buprenorphine. HealthDay News — Injectable, extended-release buprenorphine is safe and effective in ...
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results